National MS Society Responds to Price of New Biogen/Alkermes MS Medication Vumerity
November 13, 2019
November 13, 2019
NEW YORK, Nov. 13 -- The National Multiple Sclerosis Society issued the following news:
The FDA recently approved a new medication for relapsing MS, Vumerity. The drug maker, Biogen/Alkermes, released this statement along with announcing the price:
We've made the decision to launch VUMERITY in the US with the lowest annual WAC price for oral MS disease-modifying therapies at an annualized price of $88,000.
The National MS Society is releasing this statement . . .
The FDA recently approved a new medication for relapsing MS, Vumerity. The drug maker, Biogen/Alkermes, released this statement along with announcing the price:
We've made the decision to launch VUMERITY in the US with the lowest annual WAC price for oral MS disease-modifying therapies at an annualized price of $88,000.
The National MS Society is releasing this statement . . .